42 results about "Alpha-glucosidase activity" patented technology

The invention relates to lactobacillus rhamnosus CCFM0528 having an inhibitory effect on alpha-glucosidase activity, the bacterial strain is preserved at the China General Microbiological Culture Collection Center (CGMCC), and the accession number is CGMCC No.7317. Cytoplasm and fermentation supernate of the CCFM0528 can respectively exhibit the inhibitory effects on the alpha-glucosidase activity, with the inhibition rates of 29.2% and 14.1% respectively. Studies show that the CCFM0528 exhibits the inhibitory effect not only on the alpha-glucosidase activity, also on glucose transport. The experimental results show that the CCFM0528 can prevent type-2 diabetes, effectively reduce fasting blood glucose and postprandial blood glucose of mice, and improve glucose tolerance of the mice. The principle may be that the CCFM0528 has inhibitory effect on the alpha-glucosidase activity and enzyme expression amount in intestinal tract, and can influence the gene expression level of glucose-transport relating protein SGLT-1 and GLUT-2.

The invention provides extracts of brown seaweed of the genus Ascophyllum that have valuable pharmacological properties. In particular, compositions of the invention are useful for e.g.: inhibiting alpha-glucosidase activity; preventing or treating conditions mediated by alpha-glucosidase activity; reducing blood glucose levels; preventing or treating diabetes; modulating glucose uptake in adipocytes; preventing or treating obesity; scavenging free radicals; stimulating the immune system; activating macrophages; preventing or treating condition mediated by macrophage activation; and modulating nitric oxide production by macrophages. Methods for using the Ascophyllum extracts of the invention are provided, as are kits comprising Ascophyllum extracts of the invention and instructions for using the extracts.

The present invention relates to processes for producing a fermentation product comprising (a) saccharifying starch-containing material below the initial gelatinization temperature in the presence of i) from 0.001-50 AGU/g DS, preferably 0.01 to 10 AGU/g DS alpha-glucosidase activity more than the native amount of endogenous alpha-glucosidase present in the starch-containing material, and ii) from 0 (zero) to 10 FAU-F/g DS of alpha-amylase activity, and (b) fermenting using a fermenting organism. The invention also relates to an enzymatic composition for use in a process of the invention.

The invention relates to the technical field of medicines, and discloses glabrous sarcandra herb acidic polysaccharide quality product SGP-2. The glabrous sarcandra herb acidic polysaccharide is characterized in that the content of polysaccharide is over 90 percent, and the number-average molar mass is 1,000-2,000KDa; monosaccharide comprises glucose, galactose, mannose, arabinose and galacturonic acid; the bond types of glucosidic bond comprise alpha(1->4)galacturonic acid, alpha(1->4) galacturonic acid methyl ester, alpha(1->4) arabinose, alpha(1->4)mannose, beta(1->6) glucose, beta(1->3)galactose, alpha(1->4)glucose, beta (1->4,6)glucose, alpha(1->3,6)galactose, and alpha(1->4,6)galacturonic acid. The invention provides application of the glabrous sarcandra herb acidic polysaccharide quality product SGP-2 in inhibiting alpha-glucosidase activity and application of glabrous sarcandra herb acidic polysaccharide in preparing a medicament for treating diabetes mellitus, and provides application of the glabrous sarcandra herb acidic polysaccharide quality product SGP-2 in preparing anti-tumor medicaments.

The invention discloses an application of 3-phenylcoumarin robustic acid in a medicinal preparation for treating diabetes. Free radical removing experiments in vitro prove that the 3-phenylcoumarin robustic acid has obvious removing effects on DPPH free radicals and ABTS free radicals, and IC50 values are 1mg/ml and 0.5mg/ml respectively; the 3-phenylcoumarin robustic acid and 2,6-di-tert-butyl-4-methylphenol have similar antioxidation capabilities. At the same time, the 3-phenylcoumarin robustic acid has a good inhibition effect on alpha-glucosidase activity.

The invention discloses rubus hirsutus anthocyanin and application thereof. The rubus hirsutus anthocyanin mainly comprises cyanidin-3-O-glucoside, pelargonine 3-O-glucoside and pelargonine 3-O-rutinoside, wherein the pelargonine 3-O-glucoside is main anthocyanin. An animal experiment proves that the rubus hirsutus anthocyanin can significantly reduce fasting blood glucose of db/db diabetic mice and shows excellent hypoglycemic activity in vivo. An in-vitro experiment proves that the rubus hirsutus anthocyanin can play a hypoglycemic role by inhibiting the alpha-glucosidase activity and promoting the glucose consumption of cells. Therefore, the rubus hirsutus anthocyanin can be taken as hypoglycemic functional food or a hypoglycemic drug for the prevention and the treatment of glycometabolism disorder-related diseases. The invention provides a new idea for comprehensive development and utilization of rubus hirsutus resources in China.

The invention discloses a taxus chinensis extractive with blood sugar reduction effect. The taxus chinensis extractive is extracted from taxus chinensis plant branches and leaves by using modern separation methods. The content of refined biflavone in an effective part can be 50-80%; the main effective components are umbrella pine biflavone, ginkgetin, isoginkgetin, ginkgetin biflavone and amentoflavon. Experimental research shows that the taxus chinensis extractive can not only remarkably suppress the alpha-glucosidase activity, but also has an outstanding effect of reducing the rat blood sugar of diabetes, can relieve or suppress happening and development of diabetic complication, and has the hope to be developed into novel blood sugar reduction medicines.

The invention relates to application of clausena lansium leaves to preparation of alpha-glucosidase inhibitor products. The clausena lansium leaves are dried leaves of a rue family clausena plant clausena lansium (Lour.) Skeels. The invention further provides a composition with an alpha-glucosidase activity inhibiting effect. The composition comprises a clausena lansium leaf raw medicinal material or medicinal slices or extract of the material and other traditional Chinese medicinal materials such as coptis chinensis, panax ginseng and safflower carthamus. The composition or a preparation of the composition can be used for inhibiting the alpha-glucosidase activity, and reducing or assisting in reducing postprandial blood sugar or preventing and/or treating obesity clinically. The composition can be used as health-care food or food, and is high in safety. The preparation method is simple, and the product with the clinical effect can be obtained by adopting a conventional extraction and separation technology.

The invention discloses a novel alpha-glucosidase active inhibitor, belonging to the field of functional factors of functional foods and medicines; tea pigments in the invention can be used for strongly inhibiting alpha-glucosidase activity; the IC50 of alcohol-soluble theaflavin, the IC50 of thearubigin and the IC50 of theabrownin are 3.94 mu g/ml, 3.24 mu g/ml and 75.43 mu g/ml respectively; the half inhibition rate IC 50 of alcohol-soluble theaflavin, the half inhibition rate IC50 of thearubigin and the half inhibition rate IC50 of theabrownin are 8.19 mu g/ml, 4.50 mu g/ml and 6.98 mu g/ml respectively; the alpha-glucosidase inhibition effect of alcohol-soluble tea pigments or water-soluble tea pigments is far prior to that of the common hypoglycemic medicine, namely acarbose (acarbose IC50=1.04 mg/ml); and therefore, the novel alpha-glucosidase active inhibitor can be used as a food additive or a medicine for treating diabetes. Because of being pure natural pigments extracted from tea leaves, the tea pigments are safe, nontoxic and better in blood sugar decreasing effect; the advantages of the tea pigments are imponderable by acarbose; and therefore, the novel alpha-glucosidase active inhibitor has the application prospect for being developed into a health-care product or a novel hypoglycaemic medicine.

The invention relates to novel uses of plant extract and especially relates to novel uses of camellia oleifera cake polysaccharide. The invention provides the use of camellia oleifera cake polysaccharide in inhibition of alpha-glucosidase activity and also provides the use of camellia oleifera cake polysaccharide in preparation of a drug for treating diabetes.

The invention discloses spatial lactobacillus plantarum SS18-5 for reducing alpha-glucosidase activity and application thereof, and particularly provides lactobacillus plantarum Fullarton-SS18-5 the preservation number of which is CGMCC NO.14917. With original lactobacillus plantarum GS18 on the ground to serve as a contrast, the spatial lactobacillus plantarum Fullarton-SS18-5 which has a prettyhigh resistance rate on the alpha-glucosidase activity, namely high yield of alpha-glucosidase inhibitors, is screened out; the spatial lactobacillus plantarum SS18-5 is excellent in capability of tolerating inverse environment of a gastrointestinal tract and capable of successfully exerting a healthcare efficacy through the gastrointestinal tract, and can become the most potential bacterial strain for preventing and treating diabetes.

The invention discloses a beclomethasone dipropionate pharmaceutical composition and an application thereof in biological medicines; the beclomethasone dipropionate pharmaceutical composition provided by the invention contains beclomethasone dipropionate and a natural product compound (I) having a novel structure and separated from dried tubers of alisma orientalis; the composition of the beclomethasone dipropionate and the compound (I) can significantly improve the sugar tolerance amount of diabetic model mice, inhibits alpha-glucosidase activity, and also improves the ability of the diabetic model mice to resist oxidative injury. The activity of the composition of the beclomethasone dipropionate and the compound (I) is stronger than single activity of the beclomethasone dipropionate or the compound (I); and the composition can be developed into a drug for treating diabetes, and has prominent substantive characteristics and obvious progress compared with the prior art.

The invention relates to a preparation method of a kidney bean agglutinin with low blood coagulation activity and high and alpha-glucosidase activity. The preparation method disclosed by the invention specifically comprises the following steps: preparing a kidney bean crude extract; precipitating via ammonium sulfate; carrying out affinity chromatography; carrying out ion-exchange chromatography; homogenizing at a pressure of 10-50 MPa; treating via a pulse electric field at an electric field strength of 5-50 kV/cm; and taking the treated kidney bean agglutinin, freezing and drying to obtain kidney bean agglutinin powder. According to the discovery of the invention, after the kidney bean agglutinin is treated by the method, compared with the thermal treatment carried out for 20-40 minutes at the temperature of 80-120 DEG C, the blood coagulation activity of the kidney bean agglutinin is reduced and most of alpha-glucosidase inhibitory activity is kept, namely, on the one hand, the nutrition resistance of the kidney beans is greatly reduced and on the other hand, the beneficial alpha-glucosidase inhibitory activity is improved.

The invention discloses a method for preparing blood sugar reducing peptide by a fluorescence spectrum monitoring enzyme method. The method comprises the following steps: (1) collecting fluorescence spectra of enzymolysis reaction liquid at different time; (2) acquiring peak positions of the fluorescence spectra; (3) establishing relation between the peak positions of the fluorescence spectra and an inhibiting rate of enzymolysis protein fluid to the activity of alpha glucosaccharase; (4) monitoring the inhibiting rate of the enzymolysis protein fluid to the alpha glucosaccharase in real time. According to the method, the fluorescence spectra are collected during the preparation process of the blood sugar reducing peptide, and are subjected to analytical calculation, thus the inhibiting rate of an enzymolysis reaction product to the activity of the alpha glucosaccharase can be obtained, and the advantages of convenience and quick speed are achieved; besides, a chemical reagent is not needed in a detection process, the detection cost is low, environment pollution is not caused, and compared with a wet chemical detection method, these advantages are incomparable; meanwhile, the quality of the blood sugar reducing peptide produced in an industrialized way can be improved, and therefore the product can better reduce blood sugar concentration of a glycosuria patient, thus improving the health level of people, and having great social value and huge economic value.

The invention discloses a marine microorganism derived sesterterpene Asperterpinol B derivative and a synthesis method as well as application of saccharidase. The marine microorganism derived sesterterpene Asperterpinol B derivative is an ester type derivative with a chemical formula shown as a structural formula I, an amide type derivative shown as a structural formula II, a five-membered ring dehydrated derivative shown as a structural formula III or an eight-membered ring dehydrated derivative shown as a structural formula IV, or pharmaceutically acceptable salts or stereoisomers thereof ora prodrug molecule thereof: the formula I, the formula II, the formula III and the formula IV are shown in the description, wherein R0 is X-substituted alkane, alkene, alkyne, cycloalkane or phenyl with the carbon atom number of 1 to 10, ; X is H, Cl, Br, F, I, CN, NO2, CF3, OH, OCH3, COOH or COOCH3; R1 and R2 are alkane, alkene, alkyne, cycloalkane, N/O/S heterocycle or phenyl with the carbon atom number of 1 to 10; X is H, Cl, Br, F, I, CN, NO2, CF3, OH, OCH3, COOH or COOCH3. According to the marine microorganism derived sesterterpene Asperterpinol B derivative provided by the invention, anAsperterpinol B structure is modified to obtain a series of compounds with very good alpha-glucosidase activity and a new candidate drug molecule is provided for clinical treatment of diabetes mellitus.

The invention discloses application of golden camellia seed extractive to alpha-glucosidase inhibitor, in particular to a health care product and a medicine applied to the prevention and the curing ofthe type 2 diabetes mellitus. An in vitro alpha-glucosidase activity model is adopted for investigating the inhibition function of golden camellia seed alcohol extracts and the ethyl acetate part, the n-butyl alcohol part and the aqueous layer part of the alcohol extract for the alpha-glucosidase, and an inhibition type is determined through a Lineweave-Burk plotting method. The preparation method for a target product is simple, is easy in operation, has a potential of industrial production and can be used for the development application of the alpha-glucosidase inhibitor in natural products,and an inhibition rate for the alpha-glucosidase is superior to that of clinic medicine acarbose.

The invention provides novel pharmaceutical application of acankoreanogenin, in particular to application of acankoreanogenin to preparation of medicines for treating diabetes and further provides a pharmaceutical composition with acankoreanogenin serving as an active component. The acankoreanogenin is capable of inhibiting alpha-glucosidase activity to lower the blood glucose level of mice with spontaneous obesity diabetes and is widely applicable to preparation of the medicines for treating diabetes.

The invention relates to an alpha-glucosidase activity inhibition component in habenaria ciliolaris kranzl, and a preparation method and application of the alpha-glucosidase activity inhibition component, belonging to the fields of chemistry and chemical engineering. The preparation method comprises the following steps: crushing the habenaria ciliolaris kranzl until the particle size of the crushed habenaria ciliolaris kranzl is 420-580mu m; mixing an extracting agent and the crushed habenaria ciliolaris kranzl according to a first solid-liquid ratio of (20-100g): (500-6000mL), and extracting for 20-50h to obtain a crude habenaria ciliolaris kranzl extract; filtering, collecting supernatant, and concentrating to obtain extractum of the crude extract; dispersing the extractum of the crude extract into water according to a second solid-liquid ratio of 1g: (1-6mL), carrying out gradient elution on a sample solution in a macroporous adsorption resin chromatography column, and collecting and concentrating methyl alcohol elution peak with activity to obtain the activity inhibition component. The method is simple and easy to operate. The alpha-glucosidase activity inhibition component prepared by the method has stronger alpha-glucosidase inhibition activity, and has a better inhibiting effect especially for the activity of maltase.

The invention relates to a hypoglycemic application of piperlongumine alkaloids. The piperlongumine alkaloids comprise retrofractamide B and guineensine, in vitro alpha-glucosidase activity determination are performed on retrofractamide B and guineensine, results show that retrofractamide B and guineensine in the piperlongumine alkaloids have relatively good inhibitory effect on alpha-glucosidaseactivity and can be used for preparing drugs for treating diabetes, and a favorable material basis is provided for development of piperlongumine alkaloid drugs for treating diabetes.

A natural composition that includes C. osmophloeum and C. pinnatifida. The C. osmophloeum is an aqueous extract of Cinnamomum osmophloeum leaves. The Crataegus pinnatifida is an aqueous extract of C. pinnatifida fruit. The weight ratio of the C. osmophloeum to the C. pinnatifida is 1:0.05-2, the preferred ratio is 1:0.5-1.5, and the optimal ratio is 1:0.9-1.1. The pharmaceutical composition has an α-glucosidase inhibition effect. The natural composition can further inhibit α-amylase to regulate the absorption of blood glucose and carbohydrate.